I'm LongbridgeAI, I can summarize articles.Veeva's AI healthcare tools drive tangible growth while JinkoSolar's pivot fails to mask solar overcapacity. Rumble's compute deal faces rate pressures, Absci advances AI drug trials, and Petrobras dominates energy with record output. Market increasingly separates real AI value from hype.
When every earnings call name-drops AI, the market is finally drawing lines between substance and spin. Veeva Systems (VEEV.US) just proved the difference: its Falcon Safety launch and CRM dominance drove a post-earnings surge as life science clients doubled down. Meanwhile, JinkoSolar (JKS.US) scrambles to rebrand as an AI investor while hemorrhaging cash from solar overcapacity—a pivot that fooled no one after its Q2 loss widened. Rumble (RUM.US) scored a $137 billion Anthropic deal but faces headwinds from soaring Treasury yields, exposing the fragility of compute-hype plays.
Biotech’s Absci (ABSI.US) stands apart with tangible progress—its AI-designed PRLR antibody advancing to Phase 2 trials, sending shares soaring 21% weekly. Contrast that with Rezolve AI (RZLV.US), whose 1,970% revenue jump masked unsustainable losses, triggering a 17% post-earnings plunge. Even traditional giants like ITOCHU Corporation (ITOCY.US) now test AI for commodity accounting, though analysts question if such pilots move the needle. Petrobras (PBR.A.US) quietly crushed records with 270k bpd output growth, proving old-school energy still prints money when oil markets cooperate.
Amid the noise, Gaotu Techedu (GOTU.US) highlights a darker trend: aggressive sales tactics overshadowing its AI education push, while MXLL (MXLL.US) and SHMDW (SHMDW.US) linger in obscurity with no material updates. The lesson? AI isn’t a magic wand—it’s a spotlight on who’s building real value versus chasing buzzwords.